Literature DB >> 12441013

Comprehensive management of hypertensive emergencies and urgencies.

George A Mansoor1, William H Frishman.   

Abstract

Despite advances in chronic hypertension management, hypertensive emergencies and urgencies remain as serious complications. Much of this relates to poor compliance with effective antihypertensive management. Hypertensive emergencies and urgencies can also be seen as the initial manifestations of hypertension in pregnancy and in the perioperative period. Multiple classes of intravenous antihypertensive drugs are available to treat hypertensive emergencies, and specific agents may have an advantage in a given clinical situation. Orally active agents are used to treat hypertensive urgencies, and include clonidine, angiotensin-converting enzyme inhibitors, and labetalol. Most patients respond to drug therapy, but problems may arise related to a rapid normalization of blood pressure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441013     DOI: 10.1097/00132580-200211000-00005

Source DB:  PubMed          Journal:  Heart Dis        ISSN: 1521-737X


  6 in total

1.  Substrate specificity and mechanism of the intestinal clonidine uptake by Caco-2 cells.

Authors:  Wiebke Fischer; Linda Metzner; Kathrin Hoffmann; Reinhard H H Neubert; Matthias Brandsch
Journal:  Pharm Res       Date:  2006-12-13       Impact factor: 4.200

2.  High-Risk Patients with Hypertension: Clinical Management Options.

Authors:  Candace D McNaughton; Wesley H Self; Phillip D Levy; Tyler W Barrett
Journal:  Clin Med Rev Vasc Health       Date:  2013-10-08

Review 3.  Pathophysiology and medical management of systemic hypertension in preeclampsia.

Authors:  William H Frishman; Megan Veresh; Stacy J Schlocker; Nergesh Tejani
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

4.  Transport of clonidine at cultured epithelial cells (JEG-3) of the human placenta.

Authors:  Johanna Müller; Reinhard Neubert; Matthias Brandsch
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

Review 5.  β-Adrenergic blockers.

Authors:  William H Frishman; Elijah Saunders
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-08-08       Impact factor: 3.738

6.  CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department.

Authors:  W Frank Peacock; Joseph Varon; Brigitte M Baumann; Pierre Borczuk; Chad M Cannon; Abhinav Chandra; David M Cline; Deborah Diercks; Brian Hiestand; A Hsu; Preeti Jois-Bilowich; Brian Kaminski; Philip Levy; Richard M Nowak; Jon W Schrock
Journal:  Crit Care       Date:  2011-06-27       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.